Clinical Experience with Leuprorelin Acetate in the Treatment of Endometriosis.
- Author:
Sung Hoon KIM
1
;
Yong Soon KWON
;
Young Mi OH
;
Bang Hyun LEE
;
Hee Dong CHAE
;
Chung Hoon KIM
;
Byung Moon KANG
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Lorelin(R);
Endometriosis;
Gonadotropin releasing hormone agonist (GnRH)
- MeSH:
Arthralgia;
Endometriosis*;
Estradiol;
Female;
Humans;
Korea;
Leuprolide*;
Liver;
Luteinizing Hormone;
Nausea
- From:Korean Journal of Obstetrics and Gynecology
2003;46(3):575-580
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the clinical efficacy and safety of Lorelin(R), a depot form of leuprorelin acetate made in Korea, in the treatment of endometriosis. MATERIALS AND METHODS: Twenty patients with surgically proven endometriosis were recruited and followed during about 21 weeks of treatment. Lorelin(R) 3.75 mg was injected every 4 weeks after the first injection following initial operation and a total of six doses were injected to a patient. Symptom severity score, chemical battery, lipid battery, and serum levels of follicule stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and CA-l25 were assayed before Lorelin(R) treatment, after 3 doses, and after 6 doses. Statistical analysis was performed utilizing repeated analysis of variance (ANOVA) and results with P-value less than 0.05 were considered significant. RESULTS: The age range at initial operation was 25 to 48 and the mean age was 36.5+/-6.1 (mean+/-SD) years. Symptom severity score and serum levels of LH, FSH, E2, and CA-125 were significantly lower after 3 and 6 doses of Lorelin(R) than before treatment. Transient elevation of liver enzyme was observed in 2 patients after 3 doses of Lorelin(R). Side effects were mainly due to treatment-induced hypoestrogenism and the most frequent symptom was hot flush (55%), vaginal dryness (30%), transient nausea sense (25%), and arthralgia (25%). All patients were able to tolerate these symptoms and no one discontinued Lorelin(R) therapy. CONCLUSION: This study suggests that Lorelin(R) could be an effective and safe regimen in the treatment of endometriosis.
